StockData
BioMarin Pharmaceutical Inc logo

BioMarin Pharmaceutical Inc (BMRN) stock

BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/3093% above fair value
$58.51+0.52 (+0.90%)

Close on Nov 17, 2026Market cap $11.33BP/E 154.0Yield –

BioMarin Pharmaceutical total assets

Total assets on the balance sheet at the end of each period.

BioMarin Pharmaceutical's total assets was $11.72B at Jun 30, 2026. For fiscal 2025 it was $7.59B, up 8.7% from the year before. Over ten years it grew 7.4% a year on average. The highest annual figure on record is $7.59B in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$7.59B+8.7%
FY2024Dec 31, 2024$6.99B+2.2%
FY2023Dec 31, 2023$6.84B+7.3%
FY2022Dec 31, 2022$6.38B+6.2%
FY2021Dec 31, 2021$6.00B+2.7%
FY2020Dec 31, 2020$5.85B+24.7%
FY2019Dec 31, 2019$4.69B+5.9%
FY2018Dec 31, 2018$4.43B-4.4%
FY2017Dec 31, 2017$4.63B+15.1%
FY2016Dec 31, 2016$4.02B+7.9%
FY2015Dec 31, 2015$3.73B+50.7%
FY2014Dec 31, 2014$2.48B+10.3%
FY2013Dec 31, 2013$2.24B+43.1%
FY2012Dec 31, 2012$1.57B+20.1%
FY2011Dec 31, 2011$1.31B+3.4%
FY2010Dec 31, 2010$1.26B+37.7%
FY2009Dec 31, 2009$917.16M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$11.72B+57.2%
Q1 FY2026Mar 31, 2026$8.59B+20.2%
Q4 FY2025Dec 31, 2025$7.59B+8.7%
Q3 FY2025Sep 30, 2025$7.61B+11.1%
Q2 FY2025Jun 30, 2025$7.46B+5.5%
Q1 FY2025Mar 31, 2025$7.15B+4.0%
Q4 FY2024Dec 31, 2024$6.99B+2.2%
Q3 FY2024Sep 30, 2024$6.85B+1.4%
Q2 FY2024Jun 30, 2024$7.07B+7.7%
Q1 FY2024Mar 31, 2024$6.87B+6.8%
Q4 FY2023Dec 31, 2023$6.84B+7.3%
Q3 FY2023Sep 30, 2023$6.76B+7.9%
Q2 FY2023Jun 30, 2023$6.56B+6.8%
Q1 FY2023Mar 31, 2023$6.43B+6.1%
Q4 FY2022Dec 31, 2022$6.38B+6.2%
Q3 FY2022Sep 30, 2022$6.26B+4.8%
Q2 FY2022Jun 30, 2022$6.15B+4.2%
Q1 FY2022Mar 31, 2022$6.06B+4.4%
Q4 FY2021Dec 31, 2021$6.00B+2.7%
Q3 FY2021Sep 30, 2021$5.98B-2.9%
Q2 FY2021Jun 30, 2021$5.90B+11.2%
Q1 FY2021Mar 31, 2021$5.81B+22.9%
Q4 FY2020Dec 31, 2020$5.85B+24.7%
Q3 FY2020Sep 30, 2020$6.16B+35.1%
Q2 FY2020Jun 30, 2020$5.30B+20.7%
Q1 FY2020Mar 31, 2020$4.72B+6.5%
Q4 FY2019Dec 31, 2019$4.69B+5.9%
Q3 FY2019Sep 30, 2019$4.56B-2.9%
Q2 FY2019Jun 30, 2019$4.39B-5.0%
Q1 FY2019Mar 31, 2019$4.44B-3.5%
Q4 FY2018Dec 31, 2018$4.43B-4.4%
Q3 FY2018Sep 30, 2018$4.70B+2.5%
Q2 FY2018Jun 30, 2018$4.62B+15.0%
Q1 FY2018Mar 31, 2018$4.60B+16.7%
Q4 FY2017Dec 31, 2017$4.63B+15.1%
Q3 FY2017Sep 30, 2017$4.58B+19.2%
Q2 FY2017Jun 30, 2017$4.02B–
Q1 FY2017Mar 31, 2017$3.94B–
Q4 FY2016Dec 31, 2016$4.02B–
Q3 FY2016Sep 30, 2016$3.84B–

More BioMarin Pharmaceutical figures

See a number that looks wrong?